NCT00469040View on ClinicalTrials.gov

Safety, Blood Levels and Effects of GW642444

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

April 16, 2007

Study Completion Date

April 16, 2007

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GW642444M for 14 days

M salt

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00469040 - Safety, Blood Levels and Effects of GW642444 | Biotech Hunter | Biotech Hunter